Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.

Many patients with advanced Parkinson's disease (PD) experience motor complications, which negatively impact quality of life, despite optimized oral therapy. It is important for patients to have a treatment option that may provide rapid relief from "off" episodes. In three pivotal, randomized, placebo-controlled trials, subcutaneous apomorphine was effective in acutely treating "off" episodes, significantly improving Unified Parkinson Disease Rating Scale motor scores and reducing the number of "off" hours per day, with a significantly shorter time to patient-declared onset of relief than placebo. Thus, clinical trial data support the efficacy of intermittent subcutaneous apomorphine as a rapid acute treatment for "off" episodes in advanced PD.
AuthorsMark Stacy, Dee Silver
JournalParkinsonism & related disorders (Parkinsonism Relat Disord) Vol. 14 Issue 2 Pg. 85-92 ( 2008) ISSN: 1353-8020 [Print] England
PMID18083605 (Publication Type: Journal Article, Review)
Chemical References
  • Antiparkinson Agents
  • Apomorphine
  • Antiparkinson Agents (administration & dosage, adverse effects, therapeutic use)
  • Apomorphine (administration & dosage, adverse effects, therapeutic use)
  • Humans
  • Injections, Subcutaneous
  • Parkinson Disease (drug therapy, psychology)
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Registries

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: